Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1989 Jan;83(1):66–73. doi: 10.1172/JCI113886

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.

M S Sheikh 1, J A Maguire 1, M Emmett 1, C A Santa Ana 1, M J Nicar 1, L R Schiller 1, J S Fordtran 1
PMCID: PMC303644  PMID: 2910921

Abstract

Antacids used to decrease phosphorus absorption in patients with renal failure may be toxic. To find more efficient or less toxic binders, a three-part study was conducted. First, theoretical calculations showed that phosphorus binding occurs in the following order of avidity: Al3+ greater than H+ greater than Ca2+ greater than Mg2+. In the presence of acid (as in the stomach), aluminum can therefore bind phosphorus better than calcium or magnesium. Second, in vitro studies showed that the time required to reach equilibrium varied from 10 min to 3 wk among different compounds, depending upon solubility in acid and neutral solutions. Third, the relative order of effectiveness of binders in vivo was accurately predicted from theoretical and in vitro results; specifically, calcium acetate and aluminum carbonate gel were superior to calcium carbonate or calcium citrate in inhibiting dietary phosphorus absorption in normal subjects. We concluded that: (a) inhibition of phosphorus absorption by binders involves a complex interplay between chemical reactions and ion transport processes in the stomach and small intestine; (b) theoretical and in vitro studies can identify potentially better in vivo phosphorus binders; and (c) calcium acetate, not previously used for medical purposes, is approximately as efficient as aluminum carbonate gel and more efficient as a phosphorus binder than other currently used calcium salts.

Full text

PDF
66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfrey A. C., LeGendre G. R., Kaehny W. D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976 Jan 22;294(4):184–188. doi: 10.1056/NEJM197601222940402. [DOI] [PubMed] [Google Scholar]
  2. Alon U., Davidai G., Bentur L., Berant M., Better O. S. Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab. 1986;12(5-6):320–325. [PubMed] [Google Scholar]
  3. Andreoli S. P., Dunson J. W., Bergstein J. M. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis. 1987 Mar;9(3):206–210. doi: 10.1016/s0272-6386(87)80056-2. [DOI] [PubMed] [Google Scholar]
  4. Bo-Linn G. W., Davis G. R., Buddrus D. J., Morawski S. G., Santa Ana C., Fordtran J. S. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984 Mar;73(3):640–647. doi: 10.1172/JCI111254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bricker N. S. On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis". N Engl J Med. 1972 May 18;286(20):1093–1099. doi: 10.1056/NEJM197205182862009. [DOI] [PubMed] [Google Scholar]
  6. Bricker N. S., Slatopolsky E., Reiss E., Avioli L. V. Caclium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med. 1969 May;123(5):543–553. [PubMed] [Google Scholar]
  7. Cushner H. M., Copley J. B., Lindberg J. S., Foulks C. J. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int. 1988 Jan;33(1):95–99. doi: 10.1038/ki.1988.15. [DOI] [PubMed] [Google Scholar]
  8. Davis G. R., Zerwekh J. E., Parker T. F., Krejs G. J., Pak C. Y., Fordtran J. S. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology. 1983 Oct;85(4):908–916. [PubMed] [Google Scholar]
  9. Fordtran J. S., Locklear T. W. Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis. 1966 Jul;11(7):503–521. doi: 10.1007/BF02233563. [DOI] [PubMed] [Google Scholar]
  10. Fordtran J. S., Morawski S. G., Richardson C. T. In vivo and in vitro evaluation of liquid antacids. N Engl J Med. 1973 May 3;288(18):923–928. doi: 10.1056/NEJM197305032881801. [DOI] [PubMed] [Google Scholar]
  11. Gonella M., Calabrese G., Vagelli G., Pratesi G., Lamon S., Talarico S. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment. Clin Nephrol. 1985 Sep;24(3):147–150. [PubMed] [Google Scholar]
  12. Hercz G., Kraut J. A., Andress D. A., Howard N., Roberts C., Shinaberger J. H., Sherrard D. J., Coburn J. W. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab. 1986;12(5-6):314–319. [PubMed] [Google Scholar]
  13. Hodsman A. B., Sherrard D. J., Alfrey A. C., Ott S., Brickman A. S., Miller N. L., Maloney N. A., Coburn J. W. Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab. 1982 Mar;54(3):539–546. doi: 10.1210/jcem-54-3-539. [DOI] [PubMed] [Google Scholar]
  14. Larson E. A., Ash S. R., White J. L., Hem S. L. Phosphate binding gels: balancing phosphate adsorption and aluminum toxicity. Kidney Int. 1986 Jun;29(6):1131–1135. doi: 10.1038/ki.1986.118. [DOI] [PubMed] [Google Scholar]
  15. Lennon E. J., Lemann J., Jr, Litzow J. R. The effects of diet and stool composition on the net external acid balance of normal subjects. J Clin Invest. 1966 Oct;45(10):1601–1607. doi: 10.1172/JCI105466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Moriniere P., Roussel A., Tahiri Y., de Fremont J. F., Maurel G., Jaudon M. C., Gueris J., Fournier A. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc. 1983;19:784–787. [PubMed] [Google Scholar]
  17. O'Hare J. A., Callaghan N. M., Murnaghan D. J. Dialysis encephalopathy. Clinical, electroencephalographic and interventional aspects. Medicine (Baltimore) 1983 May;62(3):129–141. [PubMed] [Google Scholar]
  18. O'Hare J. A., Murnaghan D. J. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. N Engl J Med. 1982 Mar 18;306(11):654–656. doi: 10.1056/NEJM198203183061107. [DOI] [PubMed] [Google Scholar]
  19. Ramirez J. A., Emmett M., White M. G., Fathi N., Santa Ana C. A., Morawski S. G., Fordtran J. S. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986 Nov;30(5):753–759. doi: 10.1038/ki.1986.252. [DOI] [PubMed] [Google Scholar]
  20. Read N. W., Miles C. A., Fisher D., Holgate A. M., Kime N. D., Mitchell M. A., Reeve A. M., Roche T. B., Walker M. Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea. Gastroenterology. 1980 Dec;79(6):1276–1282. [PubMed] [Google Scholar]
  21. Rubini M. E., Cobun J. W., Massry S. G., Shinaberger J. H. Renal osteodystrophy; some therapeutic consideration relative to long-term dialysis and transplantation. Arch Intern Med. 1969 Dec;124(6):663–669. doi: 10.1001/archinte.124.6.663. [DOI] [PubMed] [Google Scholar]
  22. Rutherford W. E., Bordier P., Marie P., Hruska K., Harter H., Greenwalt A., Blondin J., Haddad J., Bricker N., Slatopolsky E. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest. 1977 Aug;60(2):332–341. doi: 10.1172/JCI108781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sheikh M. S., Santa Ana C. A., Nicar M. J., Schiller L. R., Fordtran J. S. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987 Aug 27;317(9):532–536. doi: 10.1056/NEJM198708273170903. [DOI] [PubMed] [Google Scholar]
  24. Slatopolsky E., Caglar S., Gradowska L., Canterbury J., Reiss E., Bricker N. S. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 1972 Sep;2(3):147–151. doi: 10.1038/ki.1972.84. [DOI] [PubMed] [Google Scholar]
  25. Slatopolsky E., Caglar S., Pennell J. P., Taggart D. D., Canterbury J. M., Reiss E., Bricker N. S. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest. 1971 Mar;50(3):492–499. doi: 10.1172/JCI106517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Slatopolsky E., Weerts C., Lopez-Hilker S., Norwood K., Zink M., Windus D., Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med. 1986 Jul 17;315(3):157–161. doi: 10.1056/NEJM198607173150304. [DOI] [PubMed] [Google Scholar]
  27. Swartz R., Dombrouski J., Burnatowska-Hledin M., Mayor G. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity. Am J Kidney Dis. 1987 Mar;9(3):217–223. doi: 10.1016/s0272-6386(87)80058-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES